Premium
Ruxolitinib resistance or intolerance in steroid‐refractory acute graft‐ versus ‐host disease — a real‐world outcomes analysis
Author(s) -
Abedin Sameem,
Rashid Nahid,
Schroeder Mark,
Romee Rizwan,
Nauffal Mary,
Alhaj Moustafa Muhamad,
KharfanDabaja Mohamed A.,
Palmer Jeanne,
Hogan William,
Hefazi Mehrdad,
Larson Samantha,
Holtan Shernan,
DeFilipp Zachariah,
Jayani Reena,
Dholaria Bhagirathbhai,
Pidala Joseph,
Khimani Farhad,
Grunwald Michael R.,
Butler Candace,
Hamadani Mehdi
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17700
Subject(s) - ruxolitinib , medicine , discontinuation , refractory (planetary science) , gastroenterology , disease , bone marrow , myelofibrosis , physics , astrobiology
Summary Ruxolitinib for steroid‐refractory acute graft‐ versus ‐host disease (SR‐aGVHD) results in resistance or intolerance in 1/5 of patients. Outcomes of such patients are undefined. We identified these patients in a multicentre review and reported outcomes. Ruxolitinib‐resistant aGVHD was identified in 48/307 patients. Among patients receiving additional therapy, the overall response rate to next therapy was 36%. Median survival was 21 days. Ruxolitinib intolerance led to treatment discontinuation in 16/307 patients. Ten intolerant patients received additional therapy with 50% experiencing continued improvement of aGVHD. Median survival was 50 days in these patients. These data serve as a baseline for future SR‐aGVHD studies.